Pfizer Stock Slides As Data From Covid Antiviral Trial Disappoints

Updated at 9:45 am EST

Pfizer  (PFE) – Get Pfizer Inc. Report shares moved lower Monday after the drugmaker posted disappointing late-stage data from a trial of its Covid antiviral treatment, Paxlovid, late Friday ahead of its first quarter earnings later this week.

Pfizer said a trial involving 3,000 adults with ‘household contacts’ that were infected by Covid failed to meet its primary endpoint of reducing the overall risk of infection to the person taking the drug. Patients that took a five-day course of Paxloivd were 32% less likely to be infected, Pfizer said, while those taking a ten-day course were 37% less likely. 

Source: https://www.thestreet.com/markets/pfizer-stock-slides-as-data-from-covid-antiviral-trial-disappoints?puc=yahoo&cm_ven=YAHOO&yptr=yahoo